再生元制药公司(Regeneron)今日股价大跌11.55%,引发市场广泛关注。公司盘前股价下跌5.18%,随后跌幅进一步扩大,一度重挫近10%,截至收盘仍大跌6.78%。
导致此次重挫的主要原因是公司在第三季度财报中公布的旗舰产品Eylea高剂量新版本的销售数据低于市场预期。数据显示,高剂量Eylea新药在第三季度销售额为3.92亿美元,低于分析师预期的4.17亿美元。
Eylea是再生元制药公司最重要的收入来源,被视为其摇钱树产品。新推出的高剂量版本可延长患者注射间隔时间,无疑拥有更高的临床价值和市场潜力。但销售未达预期引发市场对该公司转型战略和长期增长前景的担忧。虽然总体Eylea销售额达到15.4亿美元,同比增长3%,但新药销售放缓令投资者失望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.